On October 1, 2024, The Honorable Zahid N. Quraishi of the U.S. District Court for the District of New Jersey granted final approval of a class-action settlement resolving End-Payor Plaintiffs’ claims against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, “Pfizer”) in In re Lipitor Antitrust Litigation (MDL No. 2332). This settlement marked the culmination of over a decade of litigation concerning End-Payor Plaintiffs’ allegations that Pfizer and Ranbaxy Inc., Ranbaxy Laboratories Limited, and Ranbaxy Pharmaceuticals, Inc. (collectively, “Ranbaxy”) engaged in anticompetitive practices concerning the cholesterol-lowering drug, Lipitor.
End-Payor Plaintiffs alleged that Pfizer and Ranbaxy unlawfully kept generic versions of Lipitor off the market, thereby inflating prices for consumers and third-party payors. Under the settlement, Pfizer agreed to pay $35 million into an interest-bearing escrow account for the benefit of consumer and third-party payor class members. The settlement, which was preliminarily approved in June 2024, resolves all of the End-Payor Plaintiffs’ claims against Pfizer. WBE and co-counsel continue to litigate End-Payor Plaintiffs’ claims against Ranbaxy.
WBE remains committed to holding pharmaceutical companies accountable and ensuring fair competition in the marketplace. For more information on the Lipitor antitrust settlement or any of the firm’s other cases, please visit our website.